BRAZIL INJECTABLE DRUGS MARKET FOR HOSPITALS & AMBULATORY SETTINGS ANALYSIS

Injectable drug delivery systems are used for aesthetic treatments such as body shaping, skin tightening, and wrinkle treatment. As new treatment options there are various route of administration to enter the patient’s body such as intramuscular, intravenous, and subcutaneous as advanced in medical technology. For research and development of several antibiotics, liquid drugs, and vaccination to cure aesthetic problems, companies are investing huge amount in advanced medical technology.

According to the U.S. Food and Drug Administration, 97% of medications & vaccines are administered through injections. Major injectable drugs includes remicade, avastin, neulasta, rituxan, etc. in Brazil. 

The Brazil injectable drugs market for hospitals & ambulatory settings is estimated to be valued at US$ 7,960.0 million in 2021 and is expected to exhibit a CAGR of 8.4% over the forecast period (2021-2028).

Figure 1. Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings Value (US$ Mn), By Product Type, 2021

To learn more about this report, request sample copy

Market players are focusing on expanding production capacity in different regions globally to strengthen its position in the potential market, which is expected to boost the market growth over the forecast period.

For instance, in March 2020, Brazil initiated its National Flu Vaccination Campaign in three phases against influenza. The vaccine is indicated for anyone over 6 months of age, except those who have had allergic reactions to previous doses.

Figure 1.1 Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings Value (US$ Mn), By Product Type, 2028

To learn more about this report, request sample copy

The increasing product launches and approvals are expected to drive the market growth over the forecast period.

For instance, in August 2020, Becton Dickinson Company, a global medical technology company, announced the launch of its 11^th manufacturing facility in Mexico, which is located at Hermosillo, Sonora. The plant will manufacture and supply medical devices such as plastic packing syringes in Latin America region.

Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings – Impact of Coronavirus (Covid-19) Pandemic

The coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 260 million cases and 5.2 million deaths due to coronavirus disease (COVID-19) were reported till November 29, 2021, across the globe.

The product development has noticed profound disruption, as workers have to adjust to remote work environments to decrease lab capacity because of COVID pandemic. Clinical trials are also being severely affected with disruptions in both new enrolment and in keeping record of patient therapies. According to the clinicaltrials.gov, as of April 2020, there were more than 2,850 trials and approximately 900,000 patients enrolled at trial sites in regions that were in partial or complete lockdown due to COVID-19 restrictions. The R&D labs are operating at below 50% of normal capacity. According to the World Health Organization (WHO), in 2020 there were only 32 antibacterial treatments in clinical development, targeting the WHO’s list of priority pathogens and of these, only 6 fulfil at least one of the criteria as defined by WHO. WHO developed a list of priority pathogens for which antibiotics are urgently needed and regularly performs an analysis of the clinical and pre-clinical antibacterial pipelines during the COVID-19 pandemic. It also recently gathered experts to identify Target Product Profiles (TPPs) for the most essential and missing antibacterials.

WHO furthermore works with a variety of international partners to set up new mechanisms for driving investment and innovation in R&D.

Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings: Restraint

Growth of the Brazil injectable drugs market for hospitals and ambulatory settings is likely to be hampered in the near future, owing to various drawbacks of the Brazil healthcare system. Factors such as lack of doctors and nurses is one of the main reasons for the poor public health in the urban area. Brazil has proportionately fewer doctors compared to other developed countries.

Studies show that only 8% of Brazilian doctors are working in cities. Weak or ambiguous patent laws are also expected to limit growth of the market. Countries in Latin America have adopted different approaches for intellectual property protection. Ambiguity regarding pricing of drugs is also prevalent in the region. For example, prices of public sector pharmaceutical drugs in Latin America vary than those sold through the private sector.

Key Players

Major players operating in the Brazil injectable drugs market for hospitals & ambulatory settings include Becton, Dickinson and Company, Pfizer, Inc., Novo Nordisk A/S, Gerresheimer AG, B. Braun Medical Inc., Grifols S.A, Baxter International, Inc., Fresenius Kabi AG, Mylan N.V., Bayer AG, F. Hoffmann-La Roche AG, Farmoquimica S.A., Novartis International AG, Eli Lily and Company, União Química Farmacêutica, Nacional S.A., Cristália, Aspen Pharmacare Holdings Limited, Blau Farmaceutica S.A., Halex Istar Indústria, Farmacêutica SA, Eurofarma, Ache Laboratorios Farmaceuticos SA, Laboratorio Teuto Brasileiro S/A, EMS Pharma, and Hipolabor Farmaceutica Ltda.